CASP3 and ovarian carcinoma: Similarity, the glycosyltransferases ST6Gal I reduced the activation of caspase 3 and protected against cell death after cisplatin treatment, which indicates that ST6Gal I may be a novel contributor to cisplatin resistance in ovarian cancer [35].